全球藥品製造市場-市場規模、佔有率、成長分析：依藥物、製造流程（原料藥製造、成品製造）、依治療領域分類-產業預測（2023-2030）

Global Pharmaceutical Manufacturing Market Size, Share, Growth Analysis, By Drug, By Manufacturing process(Active pharmaceutical ingredient manufacturing, finished dosage form manufacturing), By Therapeutic area - Industry Forecast 2023-2030

出版日期: 2023年09月20日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2021年全球藥品製造市場規模為4,259億美元。預測在預測期（2023-2030年），該市場將以15.9%的年複合成長率擴張，從2023年的5721億美元成長到2030年的16071.6億美元。

全球藥品製造市場作為醫療保健領域至關重要的部門繼續蓬勃發展。該市場位於研究、開發和藥品製造領域，是由多種要素共同推動的。其中包括世界人口的成長、慢性病的增加、醫療技術的進步。對新藥、個人化醫療和生物製藥的需求是市場擴張的強大驅動力。此外，醫療保健基礎設施的普及、旨在改善醫療保健可及性的政府配合措施以及對製藥設施投資的增加也促進了整個市場的強勁成長。但值得注意的是，市場的發展並非沒有課題。嚴格的法規、與定價相關的壓力以及與智慧財產權相關的複雜性都是可能阻礙整體市場發展的潛在障礙。

全球藥品製造市場的促進因素是全球對醫療保健產品和藥品解決方案不斷成長的需求。世界人口的成長，加上慢性病和感染疾病的增加，促使藥品需求大幅增加。此外，醫療技術的進步和高齡化正在協同增加對開創性藥物和治療方法的需求。為此，藥品製造商被迫提高產能、投資研發並採用新穎的製造技術，以有效滿足新興市場不斷成長的需求。

藥品製造市場的一個重要阻礙因素是嚴格的法規環境。政府和法規機構制定嚴格的標準和基準，以確保藥品的安全性、有效性和品質。遵守這些標準需要對基礎設施、強大的品管框架和完整的文件進行大量投資。違反這些法規可能會導致嚴厲的處罰並損害公司的聲譽。此外，複雜而冗長的新藥核准流程可能會阻礙產品的快速推出，並延遲向患者提供關鍵藥物。這些複雜的法規課題為潛在的新參與企業設置了障礙，並增加了藥品生產工作固有的整體成本和時間。

該報告研究了全球藥品製造市場，並提供了市場概況，包括藥物、製造流程、治療領域、地區以及參與市場的公司概況的趨勢。

主要企業簡介
- Johnson & Johnson
- Pfizer Inc.
- Novartis International AG
- Roche Holding AG
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Gilead Sciences, Inc
- Takeda Pharmaceutical Company Limited
- Novo Nordisk A/S
- Amgen Inc.
- Bayer AG
- Astellas Pharma Inc.
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company, Limited
- Teva Pharmaceutical Industries Ltd

簡介目錄

Product Code: SQMIG35I2198

Global Pharmaceutical Manufacturing Market size was valued at USD 425.9 billion in 2021 and is poised to grow from USD 572.10 billion in 2023 to USD 1607.16 billion by 2030, at a CAGR of 15.9% during the forecast period (2023-2030).

The global pharmaceutical manufacturing market continues to flourish as a pivotal sector within the healthcare realm. Anchored in the realms of research, development, and the production of medicinal substances, this market is propelled forward by an amalgamation of factors. These encompass the upward trajectory of global population figures, the escalating incidence of chronic ailments, and the stride of medical technology's evolution. The impetus for novel pharmaceuticals, individualized medicinal approaches, and biologics acts as a formidable driving force that propels the market's expansion. Additionally, the proliferation of healthcare infrastructure, governmental initiatives aimed at enhancing healthcare accessibility, and the augmented investment in pharmaceutical manufacturing facilities collectively contribute to the robust growth of the market. Nonetheless, it's noteworthy that the market's progress is not devoid of challenges. Stringent regulations, pressures linked to pricing considerations, and complexities associated with intellectual property rights loom as potential hurdles that could impede the overall advancement of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmaceutical Manufacturing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

The global pharmaceutical manufacturing industry can be segmented into various categories based on factors such as drug type, manufacturing process, therapeutic area, and geography. In terms of drug type, the industry encompasses the production of prescription drugs, over-the-counter medications, and biologics. The manufacturing process can be divided into active pharmaceutical ingredient (API) manufacturing, finished dosage form (FDF) manufacturing, and packaging. Therapeutic areas covered by the industry include cardiovascular, oncology, central nervous system, respiratory, and infectious diseases. Geographically, the global pharmaceutical manufacturing sector is spread across major regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Driver

A catalyst propelling the global pharmaceutical manufacturing market is the escalating requisition for healthcare products and medicinal solutions on a global scale. The mounting worldwide populace, coupled with an uptick in chronic maladies and infectious ailments, has instigated a marked upswing in the demand for pharmaceutical interventions. Furthermore, progressions in medical technology and the prevalence of an aging demographic have synergistically augmented the call for pioneering pharmaceuticals and therapies. In response, pharmaceutical manufacturers are compelled to amplify their production capacities, channel investments into research and development endeavors, and embrace novel manufacturing technologies to effectively cater to the expanding market requisites.

Restraint

A prominent hindrance within the pharmaceutical manufacturing market stems from the exacting regulatory milieu. Governments and regulatory bodies institute stringent norms and benchmarks to ensure the safety, effectiveness, and caliber of pharmaceutical offerings. Adhering to these standards necessitates substantial investments in infrastructure, robust quality control frameworks, and meticulous documentation. Deviation from these regulations can lead to severe penalties and detriment to a company's repute. Furthermore, the intricate and time-intensive regulatory endorsement process for new medicinal agents can impede the swiftness of product introductions, thus prolonging the availability of vital medications to patients. These intricate regulatory challenges erect barriers for potential new entrants, thereby elevating both the overall expenses and the time frame intrinsic to pharmaceutical manufacturing endeavors.

Market Trends

A notable trend within the global pharmaceutical manufacturing arena is the escalating demand for personalized medicine and targeted therapeutic interventions. The advancements in technology and genomics have ushered in an era of precision-oriented and individualized treatments, prompting a transformation in pharmaceutical manufacturing dynamics, marked by a transition to smaller production batches and adaptable manufacturing procedures. Moreover, the pursuit of biologics and biosimilars has gained traction, propelled by the surge in chronic ailments and the necessity for groundbreaking therapies. Simultaneously, a pronounced emphasis on sustainability and ecologically conscious practices has taken root, with pharmaceutical manufacturers directing their efforts towards waste reduction, bolstering energy efficiency, and embracing environmentally friendly production protocols, aligning with both regulatory stipulations and consumer anticipations.